Skip to main content
Applied BioCode Corporation logo

Applied BioCode Corporation — Investor Relations & Filings

Ticker · 6598 ISIN · KYG0488D1051 TW Manufacturing
Open in API
Filings indexed 13 across all filing types
Latest filing 2026-05-11 AGM Information
Country TW Taiwan
Listing TW 6598

About Applied BioCode Corporation

https://www.ApBioCode.com/tw

Applied BioCode Corporation is a developer and manufacturer of high-throughput multiplex molecular diagnostic solutions. The company utilizes proprietary digital biological barcode technology to facilitate the simultaneous detection of multiple pathogens from a single clinical sample. Its primary platform, the BioCode MDx-3000, supports a range of syndromic panels, including FDA-cleared assays for gastrointestinal and respiratory infections, as well as specialized tests for SARS-CoV-2, influenza, and sexually transmitted infections. Designed to optimize laboratory workflows, the system offers customizable reporting through data masking and provides cost-effective, large-scale testing capabilities. The company’s portfolio serves clinical laboratories and research institutions by providing comprehensive pathogen detection with high sensitivity and specificity.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_6598_20260611FE2.pdf
AGM Information Classification · 90% confidence The document is titled “2026 Annual Shareholder’s General Meeting Meeting Handbook” and contains the full agenda, business report, audit committee review report, financial statements, auditor’s report, articles of association, and other exhibits provided to shareholders at the meeting. This is the set of materials distributed at the Annual General Meeting, matching the definition of AGM Information (AGM-R).
2026-05-11 English
115年年報及股東會資料 — 2026_6598_20260611F02.pdf
AGM Information Classification · 90% confidence The document is a complete meeting manual (“議事手冊”) for the company’s 2026 Annual General Meeting, containing agenda, procedural notes, the business report, audit committee report, financial statements, by-law amendments, and other attachments provided to shareholders at the AGM. It is not merely an investor presentation or a brief factsheet, nor is it the standalone Annual Report. It is clearly the set of materials prepared for and distributed at the Annual General Meeting. Therefore, it should be classified as AGM Information (AGM-R).
2026-05-11 Chinese
115年年報及股東會資料 — 2026_6598_20260611FE1.pdf
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a notice of the 2026 Annual Shareholders General Meeting, providing meeting date, venue, and detailed agenda items. It is sent to shareholders to inform them of the upcoming meeting and solicit votes on various resolutions. This falls under proxy solicitation materials for a shareholder meeting, matching the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-11 English
115年年報及股東會資料 — 2026_6598_20260611F01.pdf
Proxy Solicitation & Information Statement Classification · 92% confidence The document is an official notice to shareholders for the 115th Annual General Meeting, containing meeting details, agendas, proxy forms, instructions on electronic voting, and proxy solicitation materials. It is not the AGM presentation itself nor a simple publication announcement but specifically the proxy statement/information for the shareholder meeting.
2026-05-11 Chinese
115年年報及股東會資料 — 2026_6598_20260611F13.pdf
Proxy Solicitation & Information Statement Classification · 75% confidence The document is titled as reference materials (“股東常會各項議案參考資料”) for the company’s 115th Annual General Meeting, detailing each proposal for shareholders to review and vote on. It is clearly a set of informational materials sent out in connection with the shareholders’ meeting to explain and solicit votes on the motions. This matches the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders providing information and requesting votes.
2026-05-11 Chinese
代子公司Applied BioCode,Inc.公告所開發的20項呼吸道 多元分子檢測套組(RPP)及自動化診斷系統(MDx3000)，搭配賽默 飛世爾萃取儀器前處理系統，取得美國FDA上市許可。
Regulatory Filings
2026-05-02 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.